Octreotide

Category
peptide
Half-Life (t½)
SC: 1.5h · IV: 1.5h · IM: 1.5h
Formula
C49H66N10O10S2
Molecular Weight
1019.2 g/mol
PubChem CID
448601
Aliases
SMS 201-995, Sandostatin, Sandostatin LAR

Pharmacological Mechanism

Cyclic octapeptide with a disulfide bridge (Cys-2 – Cys-7) and D-Phe, D-Trp, Thr-ol modifications — producing 30× longer t½ than native somatostatin (1.5 h vs 2 min) and SSTR2 > SSTR5 selectivity. Suppresses GH + IGF-1 (acromegaly), inhibits hormone release from functional neuroendocrine tumours (carcinoid, VIPoma, glucagonoma), and reduces portal pressure acutely (variceal bleeding). LAR formulation: biodegradable PLGA microspheres release drug over ~4 weeks.

Half-Life & Elimination Curve (SC: 1.5h · IV: 1.5h · IM: 1.5h)

100%50%25%12.5%0%0h0×t½1.5h1×t½3h2×t½4.5h3×t½6h4×t½7.5h5×t½0×t½ (0h): 100% remaining (~3.07 µg/L)1×t½ (1.5h): 50% remaining (~1.53 µg/L)2×t½ (3h): 25% remaining (~0.767 µg/L)3×t½ (4.5h): 12.5% remaining (~0.383 µg/L)4×t½ (6h): 6.3% remaining (~0.192 µg/L)5×t½ (7.5h): 3.1% remaining (~0.0958 µg/L)
Plasma (SC)t½ Decay (1.5h)
  • 0×t½0h100% (3.07 µg/L)
  • 1×t½1.5h50% (1.53 µg/L)
  • 2×t½3h25% (0.767 µg/L)
  • 3×t½4.5h12.5% (0.383 µg/L)
  • 4×t½6h6.3% (0.192 µg/L)
  • 5×t½7.5h3.1% (0.0958 µg/L)
Elimination t½1.5h (SC)
Rate Constant (ke)0.462 h⁻¹
Time to Peak (Tmax)57m
Est. Peak (Cmax)3.07 µg/L
Clearance (CL)9.7 L/h
97% Washout (5×t½)7.5h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers

References